Characteristic | Patients No. (%) |
---|---|
Immunophenotype and FAB Category of ALL | 67 (50.4) |
B-linage-ALL | 56 (42.1) |
   Pre-B-ALL (L1 and L2) | 53 (39.8) |
   Lymphoma/leukemia B-ALL (L3) | 3 (2.3) |
T-ALL (L1 and L2) | 11 (8.3) |
FAB Category of AML | 66 (49.6) |
   M1 myeloblastic without maturation | 19 (14.3) |
   M2 myeloblastic with maturation | 13 (9.8) |
   M3 promyelocytic | 13 (9.8) |
   M4 myelomonocytic | 11 (8.3) |
   M5 monoblastic, monocytic | 5 (3.8) |
   M7 megakaryoblastic | 3 (2.3) |
   Unclassified | 2 (1.5) |